Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Endoresection utilizing pars plana vitrectomy for benign and malignant intraocular tumors

Reichstein, David; Karan, Kayla

Current Opinion in Ophthalmology: May 2019 - Volume 30 - Issue 3 - p 151–158
doi: 10.1097/ICU.0000000000000561
RETINAL, VITREOUS AND MACULAR DISORDERS: Edited by Brandon G. Busbee and John W. Kitchens

Purpose of review Endoresection of intraocular tumors is a complicated procedure utilizing pars plana vitrectomy techniques. Though it has potential downsides and complications, there is potential for this technique in the treatment of malignant and benign intraocular tumors.

Recent findings Endoresection has been utilized in some form for the last three decades, but recent advances in vitreoretinal surgery have improved the technique. Endoresection is used most commonly to treat posterior uveal melanoma, but success in treating benign tumors, such as astrocytoma or retinal capillary hemangioblastoma has emboldened surgeons to expand its indications. It appears that removal of a malignant tumor, such as uveal melanoma may spare the eye some damaging effects of radiation retinopathy and radiation optic neuropathy. These benefits may occur even when the tumor is treated concurrently with plaque brachytherapy, proton beam irradiation, or stereotactic radiotherapy. The benefits of the technique are tempered, however, by the inherent difficulties associated with performing the surgery. These include potentially severe intraoperative bleeding, recurrent rhegmatogenous retinal detachment with proliferative vitreoretinopathy, air embolism, and recurrence of the tumor at the edge of the resection. Nonetheless, endoresection has recently been used for retinoblastoma in refractory cases in order to spare the globe.

Summary Endoresection is an advanced vitreoretinal surgical technique that has potential advantages in the treatment of malignant and benign intraocular tumors.

Tennessee Retina, Nashville, TN, USA

Correspondence to David Reichstein, MD, Tennessee Retina, 345 23rd Avenue North, Suite 350, Nashville, TN 37203, USA. E-mail:

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.